Biotica Technology Ltd.

Biotica Technology ltd., was a biotech company which focused on optimised polyketide therapeutics for high-value indications.[1] Following successful partnerships with leading pharmaceutical companies including Wyeth and GSK, the company was eventually dissolved on the 12th September 2015.[2] It was estimated that about £15 million had been invested in the business.[3]

Biotica Technology Ltd.
Founded1996
HeadquartersCambridge, UK
Key people
Peter F Leadlay (Founder)
Number of employees
15-30

Their technology platform was based on manipulation of the microbial genetics to make improved analogues of natural product polyketides [4] in a similar way to Kosan Biosciences. This eventually led to a successful patent appeal at the EPO.[5]

Sanglifehrins

Sanglifehrin is a mixed polyketide / non-ribosomal peptide natural product found to be a potent cyclophilin inhibitor and antiviral. Biotica had been developing analogues of this for Hepatitis C in 2011, in particular BC556[6] and the sangamides.[7] BC556 and the sangamides were acquired by Neurovive, a Swedish mitochondrial medicine company in 2013.[8]

Rapamycins

Biotica discovered and developed analogues of rapamycin, a potent polyketide mTOR inhibitor, which were eventually licensed to Wyeth in 2006 in a deal worth up to $195 million.[9] Following acquisition of Wyeth by Pfizer, these rapalogs were reacquired by Biotica in 2011.[10]

Erythromycins

Biotica discovered and developed analogues of the polyketide antibiotic erythromycin for use in inflammatory diseases, which were licensed to GSK in 2009 in a deal worth up to £89 million.[11]

Administration and sale of assets

Following entering administration in 2012, the assets of Biotica were eventually sold for a total of £500K[12] to companies including the Swedish Pharmaceutical company Neurovive[13] and the British biotech Isomerase Therapeutics.[14]

References
  1. "Biotica Technology Linkedin page". LinkedIn. 23 March 2005. Retrieved 6 September 2023.
  2. "BIOTICA TECHNOLOGY LIMITED overview". find-and-update.company-information.service.gov.uk. Retrieved 6 September 2023.
  3. "Biotica goes into administration". McTear Williams & Wood Limited. Retrieved 6 September 2023.
  4. "Discovering Drugs from Bugs". The Naked Scientists. 20 July 2008. Retrieved 27 September 2023.
  5. "Biotica Technology Limited Wins Landmark European Patent Appeal". BioSpace. Retrieved 6 September 2023.
  6. "Biotica nominates drug candidate, BC556, a cyclophilin inhibitor to treat Hepatitis C". www.businesswire.com. 31 October 2011. Retrieved 6 September 2023.
  7. "EP Vantage Interview - Biotica heads to clinic with new hep C drug". Evaluate.com. 2 November 2011. Retrieved 6 September 2023.
  8. "NeuroVive: NeuroVive acquires highly potent, novel cyclophilin inhibitors from Biotica – Abliva". abliva.com. 11 March 2013. Retrieved 6 September 2023.
  9. "Biotica inks $195M licensing deal with Wyeth |". Fierce Biotech. Retrieved 6 September 2023.
  10. "Biotica Regains Worldwide Rights to Its Rapamycin Analogue Program |". Fierce Biotech. Retrieved 6 September 2023.
  11. "Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline;". Fierce Biotech. Retrieved 27 September 2023.
  12. "Creditors to gain from Cambridge biotech sales". McTear Williams and Wood. Retrieved 27 September 2023.
  13. "Sweden's Neurovive acquires assets from UK's Biotica". Wall Street Journal. Retrieved 27 September 2023.
  14. "Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline;". Isomerase.com. 9 December 2014. Retrieved 27 September 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.